



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AF-DX 384

Item No. 25638

CAS Registry No.: 118290-26-9
Formal Name: N-[2-[2-[(dipropylamino)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-6-oxo-11H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide
MF: C₂₇H₃₈N₆O₂
FW: 478.6
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AF-DX 384 is supplied as a solid. A stock solution may be made by dissolving the AF-DX 384 in the solvent of choice. AF-DX 384 is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas, at a concentration of approximately 10 and 50 mM, respectively.

Description

AF-DX 384 is an antagonist of M₂ and M₄ muscarinic acetylcholine receptors (K_is = 6.03 and 10 nM, respectively).¹ It is selective for M₂ and M₄ over M₁, M₃, and M₅ receptors (K_is = 30.9, 66.07, and 537.03 nM, respectively). AF-DX 384 increases acetylcholine release in the hippocampus and cortex of young and aged rats *in vivo* when infused locally at a concentration of 1 μM and in the cortex when administered intraperitoneally at a dose of 5 mg/kg.² It reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine (Item No. 14108).

References

1. Dörje, F., Wess, J., Lambrecht, G., *et al.* Antagonist binding profiles of five cloned human muscarinic receptor subtypes. *J. Pharmacol. Exp. Ther.* **256**(2), 727-733 (1991).
2. Vannucchi, M.G., Scali, C., Kopf, S.R., *et al.* Selective muscarinic antagonists differentially affect *in vivo* acetylcholine release and memory performances of young and aged rats. *Neuroscience* **79**(3), 837-846 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/18/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM